-
1 Comment
Insulet Corporation is currently in a long term uptrend where the price is trading 9.1% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.3.
Insulet Corporation's total revenue rose by 17.5% to $246M since the same quarter in the previous year.
Its net income has dropped by 444.2% to $-17M since the same quarter in the previous year.
Finally, its free cash flow fell by 2263.0% to $-71M since the same quarter in the previous year.
Based on the above factors, Insulet Corporation gets an overall score of 3/5.
Sector | Healthcare |
---|---|
Industry | Medical Devices |
CurrencyCode | USD |
Exchange | NASDAQ |
ISIN | US45784P1012 |
Target Price | 312.2657 |
---|---|
Beta | 1.3 |
Market Cap | 18B |
PE Ratio | 44.8 |
Dividend Yield | None |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PODD using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025